Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma-Bio ServPBSV -27.16%43 EBITDA Margin % is 5.85% as of Apr. 2026, which is 53% above its 10-year median of 3.83. GuruFocus rates PBSV with a GF Score™ of 43/100 and a GF Value™ of $0.58 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 663 Healthcare Providers & Services companies, Pharma-Bio Serv ranks worse than 77.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharma-Bio Serv's EBITDA for the
three
months ended in Apr. 2026 was $0.16 Mil. Pharma-Bio Serv's Revenue for the
three
months ended in Apr. 2026 was $2.70 Mil. Therefore, Pharma-Bio Serv's EBITDA margin for the quarter that ended in Apr. 2026 was 5.85%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pharma-Bio Serv EBITDA Margin % Related Terms
Pharma-Bio Serv EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pharma-Bio Serv's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBSV vs MGRX, BFRG, VYND: EBITDA Margin % Comparison
For the Health Information Services subindustry, Pharma-Bio Serv's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma-Bio Serv EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv (PBSV) has a EBITDA Margin % of 5.85% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharma-Bio Serv and its competitors. This is 53% above median its historical median of 3.83. According to the industry distribution chart, Pharma-Bio Serv ranks #512 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 77.2%.
Is Pharma-Bio Serv's EBITDA Margin % too high?
Pharma-Bio Serv's current EBITDA Margin % of 5.85% is 53% above median its 10-year median of 3.83. The Healthcare Providers & Services industry median EBITDA Margin % is 10.23. Pharma-Bio Serv's value of 5.85% is 42.8% below this industry median. Based on the distribution chart, Pharma-Bio Serv ranks #512 out of 663 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pharma-Bio Serv has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma-Bio Serv's EBITDA Margin % compare to MGRX and BFRG?
According to the Healthcare Providers & Services industry distribution chart, Pharma-Bio Serv ranks #512 out of 663 companies for EBITDA Margin %. This places Pharma-Bio Serv in the lower half of its industry. The industry median EBITDA Margin % is 10.23. Pharma-Bio Serv's value of 5.85% is 42.8% below this benchmark. While the company's 10-year median is 3.83 vs. the industry median of 10.23, Pharma-Bio Serv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.23, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma-Bio Serv's current EBITDA Margin % of 5.85% is 42.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pharma-Bio Serv and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma-Bio Serv's current EBITDA Margin % is 5.85%, which is 53% above median its own 10-year median of 3.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma-Bio Serv stock overvalued right now?
Based on GuruFocus' analysis, Pharma-Bio Serv (PBSV) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.58, compared to a current price of $0.42 — trading 27.2% below its estimated fair value. The current EBITDA Margin % is 5.85%, which is 53% above median its 10-year median of 3.83 and 42.8% below the Healthcare Providers & Services industry median of 10.23. Pharma-Bio Serv's overall GF Score™ is 43/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pharma-Bio Serv (PBSV), the current EBITDA Margin % is 5.85% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma-Bio Serv (PBSV) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma-Bio Serv stock appears to be undervalued.
The current stock price of $0.42 is trading 27.2% below its estimated GF Value™ of $0.58.
GuruFocus considers Pharma-Bio Serv to be Modestly Undervalued.
Key valuation signals for PBSV:
EBITDA Margin %: 5.85% (53% above median its 10-year median of 3.83)
GF Value™: $0.58 vs. price of $0.42 (27.2% below fair value)
Industry Position: 42.8% below the Healthcare Providers & Services median (#512 of 663)
No single metric tells the full story. See the PBSV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma-Bio Serv Inc is a compliance and technology transfer services consulting firm. It also provides microbiological testing services and chemical testing services through its laboratory testing facility in Puerto Rico. It has three reportable segments: Puerto Rico technical compliance consulting which is the key revenue driver; United States technical compliance consulting; and Europe technical compliance consulting. The company offers solutions to the pharmaceutical, chemical, biotechnology, medical devices, cosmetic and food industries, and allied products companies. It generates maximum revenue from Puerto Rico and also has its presence in United States, Europe and Other countries.
43GF Score
Get the complete analysis for PBSV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBSV has been successfully added to your 
